NDA 050734 · Pfizer
Idarubicin Hydrochloride
Idarubicin Hydrochloride · Intravenous
Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Feb 17, 1997
Approved uses
1
Original approval plus efficacy supplements
Registered trials
336
104 Phase 3, 55 recruiting
FAERS reports
1,159
1,145 serious, 253 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, and EXTRAVASATION AND TISSUE NECROSIS • Cardiomyopathy: IDAMYCIN PFS can cause myocardial damage, including acute left ventricular failure, during or after termination of therapy. The risk of cardiomyopathy is increased in patients who have received prior anthracyclines or who have pre-existing cardiac disease. Assess left ventricular cardiac function prior to initiation of IDAMYCIN PFS and during and after treatment [see Warnings and Precautions (5.1) ] . • Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including IDAMYCIN PFS [see Warnings and Precautions (5.2) ] . • Extravasation and Tissue Necrosis: Extravasation of IDAMYCIN PFS during administration can result in local tissue injury and necrosis. Immediately...
What it is approved for
From the label in effect Apr 15, 2026.
IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. IDAMYCIN PFS is an anthracycline topoisomerase inhibitor indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. (1)
Mechanism: Idarubicin hydrochloride has antimitotic and cytotoxic activity through forming complexes with the DNA, inhibiting nucleic acid synthesis, inhibiting topoisomerase II activity, and producing DNA-damaging free radicals.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 17, 1997 Original approval · Type 3 - New Dosage Form
3 products under this application
- IDARUBICIN HYDROCHLORIDE · IDARUBICIN HYDROCHLORIDE 20MG/20ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- IDAMYCIN PFS · IDARUBICIN HYDROCHLORIDE 5MG/5ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- IDARUBICIN HYDROCHLORIDE · IDARUBICIN HYDROCHLORIDE 10MG/10ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Idarubicin" as an intervention, any sponsor and status, largest first.
- Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)Pivotal-lookingStatus unknown
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyAcademic, hospital or other
NCT03390387 · 4,000 participants (planned) · Start Nov 2015 · Primary completion Nov 2020
Drug: Dexamethasone continuous; Dexamethasone intermittent and 8 more · For: Childhood Acute Lymphoblastic Leukemia
Sites: Yerevan, Armenia; Homyel, Belarus; Minsk, Belarus · 58 sites in all
University Hospital, AngersGovernment (non-federal)
NCT02416388 · 3,100 participants (planned) · Start Jan 2015 · Primary completion Jul 30, 2025
Drug: Idarubicin; Daunorubicin and 8 more · For: Acute Myeloid Leukemia (AML)
Sites: Amiens, France; Angers, France; Argenteuil, France · 56 sites in all
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
- Combination Chemotherapy in Treating Children With Acute Lymphocytic LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00002812 · 2,078 participants · Start Sep 1996 · Primary completion Mar 2006
Drug: asparaginase; cyclophosphamide and 11 more · For: Leukemia
Sites: Long Beach, California; Los Angeles, California; Orange, California · 35 sites in all
- Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid LeukemiaPivotal-lookingStatus unknown
Medical Research CouncilGovernment (non-federal)
NCT00002658 · 2,000 participants (planned) · Start Jan 1994
Drug: filgrastim; amsacrine and 8 more · For: Leukemia; Neutropenia
Sites: Cardiff, United Kingdom
- Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromePivotal-lookingCompleted
Leukemia Research FundAcademic, hospital or other
NCT00005823 · 2,000 participants (planned) · Start Dec 1998
Drug: cytarabine; daunorubicin hydrochloride and 7 more · For: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Sites: Birmingham, United Kingdom; London, United Kingdom; Cardiff, United Kingdom
Goethe UniversityAcademic, hospital or other
NCT00198991 · 1,883 participants · Start Apr 2003 · Primary completion Jun 30, 2011
Drug: Cyclophosphamide; Dexamethasone and 16 more · For: Adult Acute Lymphocytic Leukemia
Sites: Frankfurt, Germany
- Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy CombinationsPivotal-lookingStatus unknown
Cardiff UniversityAcademic, hospital or other
NCT02272478 · 1,600 participants (planned) · Start Oct 30, 2014 · Primary completion Feb 2021
Drug: Arm A Mylotarg plus DA Versus CPX-351; Arm B Vosaroxin and Decitabine and 4 more · For: Acute Myeloid Leukaemia; Myelodysplastic Syndrome
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 87 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myelosuppression195
- febrile neutropenia152
- pyrexia100
- off label use66
- white blood cell count decreased62
- pneumonia61
- platelet count decreased54
- infection53
- neutropenia51
- neutrophil count decreased49
- nausea46
- death43
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 8 |
| 2011 | 36 |
| 2012 | 27 |
| 2013 | 10 |
| 2014 | 16 |
| 2015 | 32 |
| 2016 | 16 |
| 2017 | 33 |
| 2018 | 60 |
| 2019 | 52 |
| 2020 | 46 |
| 2021 | 77 |
| 2022 | 155 |
| 2023 | 185 |
| 2024 | 140 |
| 2025 | 149 |
| 2026 | 100 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F, Avvisati G, Vignetti M, et al. · N Engl J Med 2013 · Clinical Trial, Phase III, Comparative Study
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP, Montesinos P, Kim HJ, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults.
Andrade AM, Teixeira VR, Pogue R, et al. · Cytotherapy 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
Platzbecker U, Adès L, Montesinos P, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Multicenter Study
- Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML.
Lu J, Xue SL, Wang Y, et al. · Blood 2025 · Randomized Controlled Trial, Multicenter Study
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD, Lachowiez CA, Takahashi K, et al. · J Clin Oncol 2021 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Pfizer · Also marketed as Idamycin Pfs
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.